PITTSBURGH (AP) — Mylan Inc. said Monday its generic version of Gilead Science Inc.'s HIV drug Truvada has received tentative marketing approval. The company said its version was granted tentative approval under the President's Emergency Plan for AIDS Relief. Truvada is a combination of two drugs, emtricitabine and tenofovir disoproxil fumarate, and total sales of the product grew to $2.11 billion in 2008. That made Truvada Gilead's best-selling product. Mylan's generic is made by its Indian subsidiary, Matrix Laboratories.